

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM421786

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	Notice of Succession of Agency		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Credit Suisse AG, Cayman Islands Branch		03/30/2017	Corporation: NEW YORK
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	JPMorgan Chase Bank, N.A., as Successor Agent		
<b>Street Address:</b>	Mail Code NY1-C413, 4 CMC		
<b>City:</b>	Brooklyn		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	11245-0001		
<b>Entity Type:</b>	Association: UNITED STATES		
<b>PROPERTY NUMBERS Total: 15</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	1484982	CARDIOLITE	
<b>Registration Number:</b>	1496535	NEUROLITE	
<b>Registration Number:</b>	1812837	TECHNELITE	
<b>Registration Number:</b>	1812836	TECHNELITE	
<b>Registration Number:</b>	2478324	DEFINITY	
<b>Registration Number:</b>	2628446	VIALMIX	
<b>Registration Number:</b>	2897509	QUADRAMET	
<b>Registration Number:</b>	3127726	INTELLIPIN	
<b>Registration Number:</b>	3699730	LANTHEUS MEDICAL IMAGING	
<b>Registration Number:</b>	3769439	ABLAVAR	
<b>Registration Number:</b>	3919480		
<b>Serial Number:</b>	85727915	PINSYNC	
<b>Serial Number:</b>	85727869	PINCISE	
<b>Registration Number:</b>	4743827	VYPIX	
<b>Registration Number:</b>	4731737	VUCIFIC	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8009144240		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent</i>			

OP \$390.00 1484982

TRADEMARK

*using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Phone:** 800-713-0755  
**Email:** Michael.Violet@wolterskluwer.com  
**Correspondent Name:** Michael Violet  
**Address Line 1:** 4400 Easton Commons Way  
**Address Line 2:** Suite 125  
**Address Line 4:** Columbus, OHIO 43219

<b>NAME OF SUBMITTER:</b>	Elaine Carrera
---------------------------	----------------

<b>SIGNATURE:</b>	/Elaine Carrera/
-------------------	------------------

<b>DATE SIGNED:</b>	03/30/2017
---------------------	------------

**Total Attachments: 8**

source=7. Notice of Change in Agency (Trademarks)#page1.tif  
source=7. Notice of Change in Agency (Trademarks)#page2.tif  
source=7. Notice of Change in Agency (Trademarks)#page3.tif  
source=7. Notice of Change in Agency (Trademarks)#page4.tif  
source=7. Notice of Change in Agency (Trademarks)#page5.tif  
source=7. Notice of Change in Agency (Trademarks)#page6.tif  
source=7. Notice of Change in Agency (Trademarks)#page7.tif  
source=7. Notice of Change in Agency (Trademarks)#page8.tif

**NOTICE OF SUCCESSION OF AGENCY  
REEL/FRAME 036013/0516 AND REEL/FRAME 5565/0898**

This NOTICE OF SUCCESSION OF AGENCY (this “Notice”), dated as of March 30, 2017 (the “Effective Date”), is executed by Credit Suisse AG, Cayman Islands Branch, in its capacity as administrative agent and collateral agent under the Original Agreements (as defined below) (the “Prior Agent”), and JPMorgan Chase Bank, N.A., in its capacity as administrative agent and collateral agent under the Current Agreements (as defined below) (the “Successor Agent”).

WHEREAS, pursuant to that certain Term Loan Agreement, dated as of June 30, 2015, by and among Lantheus Medical Imaging, Inc., a Delaware corporation (the “Borrower”) the Prior Agent and certain other parties thereto (the “Original Credit Agreement”), the Prior Agent and the grantors party thereto (the “Grantors”) entered into that certain Guarantee and Collateral Agreement, dated as of June 30, 2015 (the “Guarantee and Collateral Agreement”), that certain Patent Security Agreement, dated as of June 30, 2015 (the “Patent Security Agreement”) and that certain Trademark Security Agreement, dated as of June 30, 2015 (the “Trademark Security Agreement” and, together with the Original Credit Agreement, the Guarantee and Collateral Agreement and the Patent Security Agreement, collectively, the “Original Agreements”), pursuant to which the Grantors granted a security interest in and to certain collateral;

WHEREAS, the Patent Security Agreement was recorded with the United States Patent and Trademark Office on June 30, 2015 at Reel/Frame 036013/0516, with respect to the patents listed on Schedule A attached hereto;

WHEREAS, the Trademark Security Agreement was recorded with the United States Patent and Trademark Office on June 30, 2015 at Reel/Frame 005565/0898, with respect to the trademarks listed on Schedule B attached hereto; and

WHEREAS, the Original Credit Agreement and the Guarantee and Collateral Agreement were amended and restated, as of March 30, 2017 (as amended and restated, collectively, the “Current Agreements”), and in connection with the transactions under the Current Agreements, the Prior Agent, the Successor Agent, the Borrower and certain other parties have into that certain Agency Successor Agreement, dated as of March 30, 2017 (the “Agency Successor Agreement”), whereby the Prior Agent resigned as administrative agent and collateral agent and is succeeded and replaced by the Successor Agent as successor administrative agent and collateral agent;


NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:


1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Agency Successor Agreement.

2. Succession and Replacement of Agency. Pursuant to the terms and conditions set forth in the Agency Successor Agreement, the Prior Agent has ceased to be administrative agent and collateral agent in such capacities and is succeeded and replaced by the Successor Agent as administrative agent and collateral agent in such capacities. Nothing herein shall be deemed to terminate, interrupt or impair the continuity of the security interests in the collateral originally granted to the Prior Agent under the Patent Security Agreement and the Trademark Security Agreement, which security interests are now succeeded by and transferred to the Successor Agent.

IN WITNESS WHEREOF, the parties have executed this Notice effective as of the Effective  
Date:


**CREDIT SUISSE AG, CAYMAN ISLANDS  
BRANCH, as the Prior Agent**

By:   
Name: William O'Daly  
Title: Authorized Signatory

By:   
Name: Karim Rahimtoola  
Title: Authorized Signatory

[Signature Page to Notice of Change in Agency]

JPMORGAN CHASE BANK, N.A., as the Successor Agent

By:   
Name: Justin Back  
Title: Vice President

[Signature Page to Notice of Change in Agency]

Schedule A

**PATENTS**

Issued Patents

Patent	Reg. No. (App. No.)	Reg. Date (App. date)	Owner
CATIONIC LIPIDS AND THE USE THEREOF	5830430	11/03/1998	Lantheus Medical Imaging, Inc.
METHODS FOR DIAGNOSTIC IMAGING BY REGULATING THE ADMINISTRATION RATE OF A CONTRAST AGENT	6033645	03/07/2000	Lantheus Medical Imaging, Inc.
PROCESS FOR SYNTHESIZING PHOSPHODIESTERS	5919967	07/06/1999	Lantheus Medical Imaging, Inc.
METHODS FOR DIAGNOSTIC IMAGING USING A CONTRAST AGENT AND A VASODILATOR	5846517	12/08/1998	Lantheus Medical Imaging, Inc.
NOVEL INTEGRIN RECEPTOR ANTAGONISTS	6130231	10/10/2000	Lantheus Medical Imaging, Inc.
QUINOLONE VITRONECTIN RECEPTOR ANTAGONIST PHARMACEUTICALS	6524553	02/25/2003	Lantheus Medical Imaging, Inc.
THERMAL PREAMPLIFICATION OF GASEOUS PRECURSOR FILLED COMPOSITIONS	6548047	04/15/2003	Lantheus Medical Imaging, Inc.
MATRIX METALLOPROTEINASE INHIBITORS	6656448	12/02/2003	Lantheus Medical Imaging, Inc.
DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION	6676929	01/13/2004	Lantheus Medical Imaging, Inc.
PHARMACEUTICALS FOR THE IMAGING OF ANGIOGENIC DISORDERS	6800273	10/05/2004	Lantheus Medical Imaging, Inc.
CONTRAST-ENHANCED DIAGNOSTIC IMAGING METHOD FOR MONITORING INTERVENTIONAL THERAPIES	6861045	03/01/2005	Lantheus Medical Imaging, Inc.
APPARATUS AND METHODS FOR ON-LINE MONITORING OF FLUORINATED MATERIAL IN HEADSPACE OF VIAL	6943692	09/13/2005	Lantheus Medical Imaging, Inc.
IMAGING SEXUAL RESPONSE	6969507	11/29/2005	Lantheus Medical Imaging, Inc.
MATRIX METALLOPROTEINASE INHIBITORS	7060248	06/13/2006	Lantheus Medical Imaging, Inc.
CONTRAST-ENHANCED DIAGNOSTIC IMAGING METHOD FOR MONITORING INTERVENTIONAL THERAPIES	7175829	02/13/2007	Lantheus Medical Imaging, Inc.


CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING	7485283	02/03/2009	Lantheus Medical Imaging, Inc.
CONTRAST AGENTS FOR APPLICATIONS INCLUDING PERFUSION IMAGING	(12/919600)	(12/21/2010)	Lantheus Medical Imaging, Inc.
PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND	8084056	12/27/2011	Lantheus Medical Imaging, Inc.
CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING	8263042	09/11/2012	Lantheus Medical Imaging, Inc.
N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS	8361438	01/29/2013	Lantheus Medical Imaging, Inc.
COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS	(13/697287)	(11/26/2012)	Lantheus Medical Imaging, Inc.
LIGANDS FOR IMAGING CARDIAC INNERVATION	(13/916205)	(06/12/2013)	Lantheus Medical Imaging, Inc.
LIGANDS FOR IMAGING CARDIAC INNERVATION	8491868	07/23/2013	Lantheus Medical Imaging, Inc.
RADIONUCLIDE GENERATOR AND METHOD OF STERILIZATION	8569713	10/29/2013	Lantheus Medical Imaging, Inc.
-----	(14/075214)	(11/08/2013)	Lantheus Medical Imaging, Inc.
-----	(14/075233)	(11/08/2013)	Lantheus Medical Imaging, Inc.
N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS	8877157	11/04/2014	Lantheus Medical Imaging, Inc.
PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND	(14/188598)	(02/24/2014)	Lantheus Medical Imaging, Inc.
PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND	8658205	02/25/2014	Lantheus Medical Imaging, Inc.
PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND	8685441	04/01/2014	Lantheus Medical Imaging, Inc.
PREPARATION OF A LIPID BLEND AND A PHOSPHOLIPID SUSPENSION CONTAINING THE LIPID BLEND	8747892	06/10/2014	Lantheus Medical Imaging, Inc.
RADIONUCLIDE GENERATOR AND METHOD OF STERILIZATION	8822950	09/02/2014	Lantheus Medical Imaging, Inc.
N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS	(14/474566)	(09/02/2014)	Lantheus Medical Imaging, Inc.

N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS	(14/492896)	(09/22/2014)	Lantheus Medical Imaging, Inc.
COMPOSITIONS, METHODS AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS	9550000	01/24/2017	Lantheus Medical Imaging, Inc.
N-ALKOXYAMIDE CONJUGATES AS IMAGING AGENTS	8852553	10/07/2014	Lantheus Medical Imaging, Inc.
-----	(62/060291)	(10/06/2014)	Lantheus Medical Imaging, Inc.
-----	(62/098453)	(12/31/2014)	Lantheus Medical Imaging, Inc.



Schedule B

**TRADEMARKS**

Trademark	Reg. (App. No.)	No.	Reg. (App. date)	Date	Owner
CARDIOLITE	1484982		04/19/1988		Lantheus Medical Imaging, Inc.
NEUROLITE	1496535		07/19/1988		Lantheus Medical Imaging, Inc.
TECHNELITE	1812837		12/21/1993		Lantheus Medical Imaging, Inc.
<b>TechneLite</b>	1812836		12/21/1993		Lantheus Medical Imaging, Inc.
<b>DEFINITY</b>	2478324		08/14/2001		Lantheus Medical Imaging, Inc.
VIALMIX	2628446		10/01/2002		Lantheus Medical Imaging, Inc.
QUADRAMET	2897509		10/26/2004		Lantheus Medical Imaging, Inc.
INTELLIPIN	3127726		08/08/2006		Lantheus Medical Imaging, Inc.
LANTHEUS MEDICAL IMAGING	3699730		10/20/2009		Lantheus Medical Imaging, Inc.
ABLAVAR	3769439		03/30/2010		Lantheus Medical Imaging, Inc.
	3919480		02/15/2011		Lantheus Medical Imaging, Inc.
PINSYNC	(85727915)		(09/13/2012)		Lantheus Medical Imaging, Inc.
PINCISE	(85727869) ITU		(09/13/2012)		Lantheus Medical Imaging, Inc.
VYPIX	4743827		05/26/2015		Lantheus Medical Imaging, Inc.
VUCIFIC	4731737		05/05/2015		Lantheus Medical Imaging, Inc.